{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:39:39Z","timestamp":1792485579519,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The exact disease-causing mechanisms in ALS remain incompletely understood. A possible cause is inflammation of neurons. Compared to other neurodegenerative diseases, neuroinflammation is pronounced in ALS, presumably leading to disease progression and neuronal death. Patients with ALS can have neuronal autoantibodies and most notably antibody-producing cells in the cerebrospinal fluid. The CD20-binding therapeutic antibody rituximab targets these antibody-producing B-cells. Rituximab is a medication commonly used in neurology. Single patients with ALS have already been treated with rituximab, which was well tolerated. We therefore want to evaluate safety and efficacy of a treatment with rituximab in ALS patients in a double-blind placebo-controlled trial. With this trial we aim for slower disease progression and unveiling disease-causing mechanisms in ALS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 52 male and female patients older than 18\u00a0years with active sporadic ALS and disease duration of less than 24\u00a0months who are on a stable dose of riluzole (50\u00a0mg BID) should be included. Patients requiring assisted ventilation of any kind or have a known intolerance to the study medication rituximab are excluded. The study medication rituximab or placebo should be administered over a period of 52\u00a0weeks at 4 distinct time points, followed by a follow-up period of 79\u00a0weeks with 4 visits. Treatment efficacy should be evaluated using the ALS functioning scale ALSFRS-R-SE at every study visit (except safety visits). Safety will be assessed through regular laboratory analyses, adverse event (AE) and serious adverse event (SAE) monitoring, and CD20+\u2009B-cell kinetics. The primary endpoint is the change in the ALS Functional Rating Scale-Revised (ALSFRS-R-SE) from baseline to week 79. Trial sites will be at Charit\u00e9\/DZNE Berlin and DZNE Bonn.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>ALS is a rapidly progressive neurodegenerative disease with limited treatment options. Recent preclinical in vivo studies suggest that B-cell-mediated autoimmunity contributes to disease progression. This trial will evaluate whether rituximab, which specifically depletes CD20+\u2009B-cells, can slow ALS progression and provide insights into disease mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial was registered in the German WHO-recognized primary register Deutsches Register Klinische Studien DRKS (German Clinical Trials Register) on 3\/07\/2023 under registration number DRKS00030948.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-10022-z","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:26:52Z","timestamp":1792481212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ABCD-Trial: study protocol for a randomized, double-blind, placebo-controlled study in patients with Amyotrophic lateral sclerosis for the evaluation of efficacy and safety of B-Cell Depletion with rituximab (ABCD)"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8108","authenticated-orcid":false,"given":"Friederike","family":"Ufer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"R\u00f6ssling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Spottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Schaprian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja Kemmerling-de","family":"Coninck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sterl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Weydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"10022_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/srep23204","author":"A Atanasio","year":"2016","unstructured":"Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee H-C, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production and glomerulonephropathy in mice. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep23204.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"10022_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3109\/17482960903093710","volume":"11","author":"C Castrillo-Viguera","year":"2010","unstructured":"Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1\u20132):178\u201380.","journal-title":"Amyotroph Lateral Scler"},{"key":"10022_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81599-5","author":"E Conti","year":"2021","unstructured":"Conti E, Sala G, Diamanti S, Casati M, Lunetta C, Gerardi F, et al. Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-81599-5.","journal-title":"Sci Rep"},{"key":"10022_CR4","doi-asserted-by":"publisher","DOI":"10.1179\/jmt.2008.16.4.82E","author":"CE Cook","year":"2008","unstructured":"Cook CE. Clinimetrics corner: the minimal clinically important change score (MCID): a necessary pretense. J Man Manip Ther. 2008. https:\/\/doi.org\/10.1179\/jmt.2008.16.4.82E.","journal-title":"J Man Manip Ther"},{"key":"10022_CR5","doi-asserted-by":"crossref","unstructured":"Cui C, Longinetti E, Larsson H, Andersson J, Pawitan Y, Piehl F, Fang F. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study. Amyotroph Lat Scler Frontotemp Degen. 2021;22(3-4):211\u20139.","DOI":"10.1080\/21678421.2020.1861022"},{"key":"10022_CR6","doi-asserted-by":"crossref","unstructured":"Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Archiv Neurol. 1990;47(11):1210\u20136.","DOI":"10.1001\/archneur.1990.00530110068019"},{"issue":"3\u20134","key":"10022_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/21678421.2022.2153607","volume":"24","author":"CN Fournier","year":"2023","unstructured":"Fournier CN, James V, Glass JD. Clinically meaningful change: evaluation of the Rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS) and the ALSFRS-R. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(3\u20134):311\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10022_CR8","doi-asserted-by":"crossref","unstructured":"Hardiman O van den Berg LH, Kiernan M. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):639\u201349.","DOI":"10.1038\/nrneurol.2011.153"},{"key":"10022_CR9","doi-asserted-by":"crossref","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, . . . HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. The New Engl J Med. 2008; 358(7):676\u201388.","DOI":"10.1056\/NEJMoa0706383"},{"key":"10022_CR10","doi-asserted-by":"crossref","unstructured":"Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, . . . Mitsumoto H. The ALSFRSr predicts survival time in an ALS clinic population. Neurol. 2005;64(1):38\u201343.","DOI":"10.1212\/01.WNL.0000148648.38313.64"},{"key":"10022_CR11","doi-asserted-by":"crossref","unstructured":"Kim SH, Huh SY, Lee S, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013; 70(9):1110\u20137.","DOI":"10.1001\/jamaneurol.2013.3071"},{"key":"10022_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01005","author":"J Liu","year":"2017","unstructured":"Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017. https:\/\/doi.org\/10.3389\/fimmu.2017.01005.","journal-title":"Front Immunol"},{"key":"10022_CR13","doi-asserted-by":"crossref","unstructured":"Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravasio A, . . . D'Alessandro R. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy. Neurological Sciences: Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2015;36(12):2243\u201352.","DOI":"10.1007\/s10072-015-2343-6"},{"key":"10022_CR14","doi-asserted-by":"crossref","unstructured":"May C, Nordhoff E, Casjens S, Turewicz M, Eisenacher M, Gold R, . . . Meyer HE. Highly Immunoreactive IgG Antibodies Directed against a Set of Twenty Human Proteins in the Sera of Patients with Amyotrophic Lateral Sclerosis Identified by Protein Array. Plos One. 2014;9(2):e89596.","DOI":"10.1371\/journal.pone.0089596"},{"key":"10022_CR15","doi-asserted-by":"crossref","unstructured":"McCombe PA, Henderson RD. The Role of immune and inflammatory mechanisms in ALS. Curr Molec Med. 2011;11(3):246\u201354.","DOI":"10.2174\/156652411795243450"},{"key":"10022_CR16","doi-asserted-by":"crossref","unstructured":"Mihajlovi\u0107 J, Bax P, van Breugel E, Blommestein HM, Hoogendoorn M, Hospes W, Postma MJ. Microcosting Study of rituximab Subcutaneous Injection Versus Intravenous Infusion. Clin Therap. 2017;39(6):1221\u201332.","DOI":"10.1016\/j.clinthera.2017.05.342"},{"key":"10022_CR17","doi-asserted-by":"crossref","unstructured":"Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern\u00e1ndez M, . . . AB10015 STUDY GROUP. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrop Late Scler Frontotemp Degen. 2024;25(1-2):5\u201314.","DOI":"10.1080\/21678421.2019.1632346"},{"key":"10022_CR18","doi-asserted-by":"crossref","unstructured":"Pullen AH, Demestre M, Howard RS, Orrell RW. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement. Acta Neuropathol. 2004;107(1):35\u201346.","DOI":"10.1007\/s00401-003-0777-z"},{"key":"10022_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1269-7","author":"H Schumacher","year":"2019","unstructured":"Schumacher H, Meyer T, Pr\u00fcss H. GABAB receptor encephalitis in a patient diagnosed with amyotrophic lateral sclerosis. BMC Neurol. 2019. https:\/\/doi.org\/10.1186\/s12883-019-1269-7.","journal-title":"BMC Neurol"},{"key":"10022_CR20","doi-asserted-by":"crossref","unstructured":"Stud Working Group. G.-1. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurol. 2017;16(7):505\u201312.","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"10022_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093932","author":"H Uenal","year":"2014","unstructured":"Uenal H, Rosenbohm A, Kufeldt J, Weydt P, Goder K, Ludolph A, et al. Incidence and geographical variation of amyotrophic lateral sclerosis (ALS) in southern Germany \u2013 completeness of the ALS registry Swabia. PLoS ONE. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0093932.","journal-title":"PLoS ONE"},{"key":"10022_CR22","doi-asserted-by":"publisher","unstructured":"Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017;10(5):537\u201349. https:\/\/doi.org\/10.1242\/dmm.029058. PMID: 28468939; PMCID: PMC5451175.","DOI":"10.1242\/dmm.029058"},{"key":"10022_CR23","doi-asserted-by":"crossref","unstructured":"Westeneng HJ, Debray TP, Visser AE, van Eijk RP, Rooney JP, Calvo A, . . . Sommer H. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-33.","DOI":"10.1016\/S1474-4422(18)30089-9"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-10022-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-10022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-10022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:03:01Z","timestamp":1792483381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-10022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10022"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-10022-z","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to the EU Regulation 536\/1014 ethics approval was granted by the Ethics Committee and the Paul Ehrlich Institute, the federal agency for vaccines and biomedicines. The responsible Ethics Committee belongs to the Technical University Munich and approves of the study. Written, informed consent to participate will be obtained from all participants. The informed consent process thoroughly explains the potential risks of rituximab, with particular emphasis on:\u2022 Infection risk: Increased susceptibility to infections due to B-cell depletion, including rare but serious infections.\u2022\u00a0Infusion reactions: Ranging from mild symptoms (fever, chills) to severe reactions (anaphylaxis). Premedication and vital sign monitoring mitigate this risk.\u2022 Prolonged B-cell depletion: B-cells may take 6\u201312\u00a0months to return to normal levels after rituximab discontinuation.All participants receive detailed written and oral information about these risks and have the opportunity to discuss concerns with the study physician before providing consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate {24}","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication {32}","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no financial or other competing interests of any of the authors.","order":3,"name":"Ethics","label":"Competing interests {28}","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"615"}}